Precision in Practice

AI’s Role in Liver Disease Detection

Liver Disease Detection White Paper
LUCEM HEALTH WHITE PAPER

Enhancing early detection and management of liver disease

Approximately one-third of the U.S. adult population is affected by liver disease1, with metabolic-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) posing significant healthcare challenges. The asymptomatic nature of these conditions in their early stages leads to underdiagnosis and delays in treatment. Our latest white paper provides a comprehensive analysis of current challenges and how AI helps provider organizations in the fight against liver disease.

This white paper provides:

  • In-depth understanding of the current landscape of liver disease prevalence, risks, and diagnostic challenges.

  • Comprehensive analysis of the economic impact of liver disease and the potential cost savings associated with early detection.

  • Insights into the latest advancements in AI technology for liver disease detection and the implications for clinical practice.

Download the liver disease detection white paper